Get started
Author

Timothy R. Mack

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
2022 · Manali Kamdar, Scott R Solomon, et al. · The Lancet · 805
PDF
Bacterial response regulators: versatile regulatory strategies from common domains
2007 · Rong Gao, Timothy R. Mack, et al. · Trends in Biochemical Sciences · 340
Structural Analysis and Solution Studies of the Activated Regulatory Domain of the Response Regulator ArcA: A Symmetric Dimer Mediated by the α4-β5-α5 Face
2005 · Alejandro Toro-Roman, Timothy R. Mack, et al. · Journal of Molecular Biology · 128
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
2021 · Manali Kamdar, Scott R. Solomon, et al. · Blood · 90
Domain Orientation in the Inactive Response Regulator Mycobacterium tuberculosis MtrA Provides a Barrier to Activation,
2007 · Natalia Friedland, Timothy R. Mack, et al. · Biochemistry · 88
Regulation of Response Regulator Autophosphorylation through Interdomain Contacts
2010 · Christopher M. Barbieri, Timothy R. Mack, et al. · Journal of Biological Chemistry · 66
PDF
Dimer Interface of the Effector Domain of Non-structural Protein 1 from Influenza A Virus
2011 · James M. Aramini, Li-Chung Ma, et al. · Journal of Biological Chemistry · 65
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
2021 · Ken Ogasawara, Michael Dodds, et al. · Clinical Pharmacokinetics · 51
PDF
Probing the Roles of the Two Different Dimers Mediated by the Receiver Domain of the Response Regulator PhoB
2009 · Timothy R. Mack, Rong Gao, et al. · Journal of Molecular Biology · 43
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
2022 · Ken Ogasawara, James Lymp, et al. · Clinical Pharmacology & Therapeutics · 39
PDF
2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)
2022 · Lina Loo, Shannon Harris, et al. · Bioanalysis · 37
PDF
Structural Analysis and Solution Studies of the Activated Regulatory Domain of the Response Rugulator Arca: a Symmetric Dimer Mediated by the Alpha4-beta5-alpha5 Face
2005 · A. Toro-Roman, Timothy R. Mack, et al. · European Journal of Soil Science · 33
Abstract C129: Antitumor efficacy and non-clinical safety of the high affinity anti-FGFR4 antibody H4: Implications for targeting the FGF19-FGFR4 axis in oncology
2015 · Timothy R. Mack, Colleen Burns Burns, et al. · Molecular Cancer Therapeutics · 1
Development and Characterization of CLYM116, a Novel Fc-Engineered Anti-APRIL Monoclonal Antibody (mAb) with pH-Dependent Binding for IgAN
2025 · Stefan Beeck, Guangzhong Lin, et al. · Journal of the American Society of Nephrology
Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
2021 · Ken Ogasawara, Michael Dodds, et al. · Clinical Pharmacokinetics
PDF
Abstract A24: Beta-klotho expression is associated with the antitumor activity of pan-FGFR inhibitor in human malignancies with FGF19 amplification
2015 · Amelie Forest, Sandra Nakasone, et al. · Molecular Cancer Therapeutics
Structure of N-terminal Domain of MtrA
2010 · C.M. Barbieri, T.R. Mack, et al. · Worldwide Protein Data Bank
Crystal structure of the response regulator protein mtrA from Mycobacterium Tuberculosis
2006 · N. Friedland, T.R. Mack, et al. · Worldwide Protein Data Bank
Crystal structure of the bef3-activated receiver domain of redox response regulator arca
2004 · A. Toro-Roman, T.R. Mack, et al. · Worldwide Protein Data Bank
Works count: 19
Citation count: 1,786
H-index: 12
I10-index: 12
Year
Topic
Type